stockportfolio.pro
Stocks / HALO vs TECH
HALO vs TECH
Halozyme Therapeutics, Inc. and Bio-Techne Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Halozyme Therapeutics, Inc. (HALO) | Bio-Techne Corporation (TECH) | |
|---|---|---|
| Market cap | $8.4B | $8.5B |
| Revenue (latest FY) | $1.40B | $1.22B |
| Net income (latest FY) | $316.89M | $73.40M |
| Revenue growth (5y CAGR) | 39.2% | 10.5% |
| Net margin | 22.7% | 6.0% |
| Return on equity | 649.2% | 3.8% |
| P/E ratio | 24.9 | 77.7 |
| Dividend yield | — | 0.6% |
| Profitable years (of last 10) | 7 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open HALO — free Open TECH — freeFrequently asked questions
Which is bigger, HALO or TECH?
Bio-Techne Corporation is larger by market capitalization — $8.5B versus $8.4B.
Which grows faster, HALO or TECH?
Over the last five fiscal years, Halozyme Therapeutics, Inc. grew revenue faster — 39.2%/yr versus 10.5%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.